{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T01:49:51Z","timestamp":1786499391550,"version":"build-2736575974"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T00:00:00Z","timestamp":1635206400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>There is evidence of increased low grade inflammation (LGI) in schizophrenia patients. However, the inter-individual variation is large and the association with demographic, somatic and psychiatric factors remains unclear. Our aim was to explore whether levels of the novel LGI marker soluble urokinase plasminogen activator receptor (suPAR) were associated with clinical factors in schizophrenia and if such associations were sex-dependent.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>In this observational study a total of 187 participants with schizophrenia (108 males, 79 females) underwent physical examination and assessment with clinical interviews (Positive and Negative Syndrome Scale (PANSS), Calgary Depression Scale for Schizophrenia (CDSS), Alcohol Use Disorder Identification Test (AUDIT), and Drug Use Disorder Identification Test (DUDIT)). Blood levels of suPAR, glucose, lipids, and high sensitivity C-reactive protein (hsCRP) were determined and body mass index (BMI) calculated. Multivariable linear regression analyses were used adjusting for confounders, and sex interaction tested in significant variables.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Adjusting for sex, age, current tobacco smoking and BMI, we found that levels of hsCRP and depressive symptoms (CDSS) were positively associated with levels of suPAR (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The association between suPAR and CDSS score was significant in females (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) but not in males. Immune activation measured by hsCRP was not associated with depressive symptoms after adjusting for BMI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our findings indicate that increased suPAR levels are associated with depressive symptoms in females with schizophrenia, suggesting aberrant immune activation in this subgroup. Our results warrant further studies, including longitudinal follow-up of suPAR levels in schizophrenia and experimental studies of mechanisms.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12888-021-03522-6","type":"journal-article","created":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:03:22Z","timestamp":1635246202000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Exploring low grade inflammation by soluble urokinase plasminogen activator receptor levels in schizophrenia: a sex-dependent association with depressive symptoms"],"prefix":"10.1186","volume":"21","author":[{"given":"Therese Torgersen","family":"Bigseth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John Abel","family":"Engh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Egeland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eivind","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Andreas","family":"Andreassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gry","family":"Bang-Kittilsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ragnhild S\u00f8rum","family":"Falk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom Langerud","family":"Holmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Mordal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmi","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils Eiel","family":"Steen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor","family":"Ueland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torkel","family":"Vang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Fredriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"issue":"1","key":"3522_CR1","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/npp.2016.211","volume":"42","author":"BJ Miller","year":"2017","unstructured":"Miller BJ, Goldsmith DR. Towards an Immunophenotype of schizophrenia: Progress, potential mechanisms, and future directions. Neuropsychopharmacology. 2017;42(1):299\u2013317. https:\/\/doi.org\/10.1038\/npp.2016.211.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"3522_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1176\/appi.ajp.2009.09030361","volume":"167","author":"AS Brown","year":"2010","unstructured":"Brown AS, Derkits EJ. Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry. 2010;167(3):261\u201380. https:\/\/doi.org\/10.1176\/appi.ajp.2009.09030361.","journal-title":"Am J Psychiatry"},{"issue":"6","key":"3522_CR3","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/schbul\/sbt200","volume":"40","author":"PR Nielsen","year":"2014","unstructured":"Nielsen PR, Benros ME, Mortensen PB. Hospital contacts with infection and risk of schizophrenia: a population-based cohort study with linkage of Danish national registers. Schizophr Bull. 2014;40(6):1526\u201332. https:\/\/doi.org\/10.1093\/schbul\/sbt200.","journal-title":"Schizophr Bull"},{"issue":"1","key":"3522_CR4","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.biopsych.2018.06.016","volume":"85","author":"AE Cullen","year":"2019","unstructured":"Cullen AE, Holmes S, Pollak TA, Blackman G, Joyce DW, Kempton MJ, et al. Associations between non-neurological autoimmune disorders and psychosis: a Meta-analysis. Biol Psychiatry. 2019;85(1):35\u201348. https:\/\/doi.org\/10.1016\/j.biopsych.2018.06.016.","journal-title":"Biol Psychiatry"},{"key":"3522_CR5","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.psychres.2019.07.005","volume":"279","author":"K Allsopp","year":"2019","unstructured":"Allsopp K, Read J, Corcoran R, Kinderman P. Heterogeneity in psychiatric diagnostic classification. Psychiatry Res. 2019;279:15\u201322. https:\/\/doi.org\/10.1016\/j.psychres.2019.07.005.","journal-title":"Psychiatry Res"},{"key":"3522_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.3389\/fpsyt.2018.00753","volume":"9","author":"RA Kroken","year":"2018","unstructured":"Kroken RA, Sommer IE, Steen VM, Dieset I, Johnsen E. Constructing the immune signature of schizophrenia for clinical use and research; an integrative review translating descriptives into diagnostics. Front Psychiatry. 2018;9:753. https:\/\/doi.org\/10.3389\/fpsyt.2018.00753.","journal-title":"Front Psychiatry"},{"issue":"4","key":"3522_CR7","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/acps.12783","volume":"136","author":"RH Morch","year":"2017","unstructured":"Morch RH, Dieset I, Faerden A, Hope S, Aas M, Nerhus M, et al. Persistent increase in TNF and IL-1 markers in severe mental disorders suggests trait-related inflammation: a one year follow-up study. Acta Psychiatr Scand. 2017;136(4):400\u20138. https:\/\/doi.org\/10.1111\/acps.12783.","journal-title":"Acta Psychiatr Scand"},{"issue":"12","key":"3522_CR8","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/mp.2016.3","volume":"21","author":"DR Goldsmith","year":"2016","unstructured":"Goldsmith DR, Rapaport MH, Miller BJ. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696\u2013709. https:\/\/doi.org\/10.1038\/mp.2016.3.","journal-title":"Mol Psychiatry"},{"key":"3522_CR9","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.psyneuen.2014.03.019","volume":"45","author":"J Dahl","year":"2014","unstructured":"Dahl J, Ormstad H, Aass HC, Malt UF, Bendz LT, Sandvik L, et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology. 2014;45:77\u201386. https:\/\/doi.org\/10.1016\/j.psyneuen.2014.03.019.","journal-title":"Psychoneuroendocrinology"},{"issue":"4","key":"3522_CR10","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41380-018-0235-x","volume":"25","author":"HQ Cai","year":"2020","unstructured":"Cai HQ, Catts VS, Webster MJ, Galletly C, Liu D, O'Donnell M, et al. Increased macrophages and changed brain endothelial cell gene expression in the frontal cortex of people with schizophrenia displaying inflammation. Mol Psychiatry. 2020;25(4):761\u201375. https:\/\/doi.org\/10.1038\/s41380-018-0235-x.","journal-title":"Mol Psychiatry"},{"issue":"5","key":"3522_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.2174\/1570159X16666180119144538","volume":"16","author":"L Orsolini","year":"2018","unstructured":"Orsolini L, Sarchione F, Vellante F, Fornaro M, Matarazzo I, Martinotti G, et al. Protein-C reactive as biomarker predictor of schizophrenia phases of illness? A systematic review. Curr Neuropharmacol. 2018;16(5):583\u2013606. https:\/\/doi.org\/10.2174\/1570159X16666180119144538.","journal-title":"Curr Neuropharmacol"},{"issue":"3","key":"3522_CR12","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ijcard.2012.03.040","volume":"167","author":"S Lyngbaek","year":"2013","unstructured":"Lyngbaek S, Sehestedt T, Marott JL, Hansen TW, Olsen MH, Andersen O, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167(3):781\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2012.03.040.","journal-title":"Int J Cardiol"},{"issue":"2","key":"3522_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.17756\/jnen.2018-039","volume":"4","author":"P Merino","year":"2018","unstructured":"Merino P, Yepes M. Urokinase-type plasminogen activator induces neurorepair in the ischemic brain. J Neurol Exp Neurosci. 2018;4(2):24\u20139. https:\/\/doi.org\/10.17756\/jnen.2018-039.","journal-title":"J Neurol Exp Neurosci"},{"issue":"1","key":"3522_CR14","doi-asserted-by":"publisher","first-page":"103","DOI":"10.31857\/S0026898420010097","volume":"54","author":"PS Klimovich","year":"2020","unstructured":"Klimovich PS, Semina EV. Mechanisms of participation of the urokinase receptor in directed axonal growth. Mol Biol (Mosk). 2020;54(1):103\u201313. https:\/\/doi.org\/10.31857\/S0026898420010097.","journal-title":"Mol Biol (Mosk)"},{"issue":"4","key":"3522_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1177\/172460080101600402","volume":"16","author":"R Riisbro","year":"2001","unstructured":"Riisbro R, Christensen IJ, Hogdall C, Brunner N, Hogdall E. Soluble urokinase plasminogen activator receptor measurements: influence of sample handling. Int J Biol Markers. 2001;16(4):233\u20139. https:\/\/doi.org\/10.1177\/172460080101600402.","journal-title":"Int J Biol Markers"},{"issue":"2","key":"3522_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/jmv.21114","volume":"80","author":"O Andersen","year":"2008","unstructured":"Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol. 2008;80(2):209\u201316. https:\/\/doi.org\/10.1002\/jmv.21114.","journal-title":"J Med Virol"},{"issue":"1","key":"3522_CR17","doi-asserted-by":"publisher","first-page":"17518","DOI":"10.1038\/s41598-018-35759-9","volume":"8","author":"L Coin-Araguez","year":"2018","unstructured":"Coin-Araguez L, Pavon FJ, Contreras A, Gentile AM, Lhamyani S, De Diego-Otero Y, et al. Inflammatory gene expression in adipose tissue according to diagnosis of anxiety and mood disorders in obese and non-obese subjects. Sci Rep. 2018;8(1):17518. https:\/\/doi.org\/10.1038\/s41598-018-35759-9.","journal-title":"Sci Rep"},{"key":"3522_CR18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.4137\/BMI.S19876","volume":"9","author":"TH Haupt","year":"2014","unstructured":"Haupt TH, Kallemose T, Ladelund S, Rasmussen LJ, Thorball CW, Andersen O, et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 2014;9:91\u2013100. https:\/\/doi.org\/10.4137\/BMI.S19876.","journal-title":"Biomark Insights"},{"issue":"1","key":"3522_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12979-018-0141-8","volume":"16","author":"TH Haupt","year":"2019","unstructured":"Haupt TH, Rasmussen LJH, Kallemose T, Ladelund S, Andersen O, Pisinger C, et al. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun Ageing. 2019;16(1):1. https:\/\/doi.org\/10.1186\/s12979-018-0141-8.","journal-title":"Immun Ageing"},{"issue":"2","key":"3522_CR20","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2011.10.039","volume":"220","author":"M Persson","year":"2012","unstructured":"Persson M, Engstrom G, Bjorkbacka H, Hedblad B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo diet and Cancer study. Atherosclerosis. 2012;220(2):502\u20135. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.10.039.","journal-title":"Atherosclerosis"},{"issue":"7","key":"3522_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.88","volume":"5","author":"M Bot","year":"2015","unstructured":"Bot M, Chan MK, Jansen R, Lamers F, Vogelzangs N, Steiner J, et al. Serum proteomic profiling of major depressive disorder. Transl Psychiatry. 2015;5(7):e599. https:\/\/doi.org\/10.1038\/tp.2015.88.","journal-title":"Transl Psychiatry"},{"key":"3522_CR22","doi-asserted-by":"publisher","first-page":"117727191770419","DOI":"10.1177\/1177271917704193","volume":"12","author":"A Gustafsson","year":"2017","unstructured":"Gustafsson A, Ventorp F, Wisen AG, Ohlsson L, Ljunggren L, Westrin A. Effects of acute exercise on circulating soluble form of the Urokinase receptor in patients with major depressive disorder. Biomark Insights. 2017;12:1177271917704193. https:\/\/doi.org\/10.1177\/1177271917704193.","journal-title":"Biomark Insights"},{"issue":"10","key":"3522_CR23","doi-asserted-by":"publisher","first-page":"e110555","DOI":"10.1371\/journal.pone.0110555","volume":"9","author":"E Haastrup","year":"2014","unstructured":"Haastrup E, Grau K, Eugen-Olsen J, Thorball C, Kessing LV, Ullum H. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One. 2014;9(10):e110555. https:\/\/doi.org\/10.1371\/journal.pone.0110555.","journal-title":"PLoS One"},{"issue":"10","key":"3522_CR24","doi-asserted-by":"publisher","first-page":"e0140052","DOI":"10.1371\/journal.pone.0140052","volume":"10","author":"F Ventorp","year":"2015","unstructured":"Ventorp F, Gustafsson A, Traskman-Bendz L, Westrin A, Ljunggren L. Increased soluble Urokinase-type plasminogen activator receptor (suPAR) levels in plasma of suicide attempters. PLoS One. 2015;10(10):e0140052. https:\/\/doi.org\/10.1371\/journal.pone.0140052.","journal-title":"PLoS One"},{"key":"3522_CR25","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.schres.2020.11.051","volume":"228","author":"TT Bigseth","year":"2021","unstructured":"Bigseth TT, Fredriksen M, Egeland J, Andersen E, Andreassen OA, Bang-Kittilsen G, et al. Elevated levels of soluble urokinase plasminogen activator receptor as a low-grade inflammation marker in schizophrenia: a case-control study. Schizophr Res. 2021;228:190\u20132. https:\/\/doi.org\/10.1016\/j.schres.2020.11.051.","journal-title":"Schizophr Res"},{"issue":"3","key":"3522_CR26","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1093\/schbul\/sbu118","volume":"41","author":"J Nielsen","year":"2015","unstructured":"Nielsen J, Roge R, Pristed SG, Viuff AG, Ullum H, Thorner LW, et al. Soluble urokinase-type plasminogen activator receptor levels in patients with schizophrenia. Schizophr Bull. 2015;41(3):764\u201371. https:\/\/doi.org\/10.1093\/schbul\/sbu118.","journal-title":"Schizophr Bull"},{"key":"3522_CR27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.psychres.2016.01.018","volume":"236","author":"A Genc","year":"2016","unstructured":"Genc A, Kalelioglu T, Karamustafalioglu N, Tasdemir A, Genc ES, Akkus M, et al. Serum soluble urokinase-type plasminogen activator receptor levels in male patients with acute exacerbation of schizophrenia. Psychiatry Res. 2016;236:179\u201381. https:\/\/doi.org\/10.1016\/j.psychres.2016.01.018.","journal-title":"Psychiatry Res"},{"issue":"10","key":"3522_CR28","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1017\/S0033291718004142","volume":"49","author":"RH Morch","year":"2019","unstructured":"Morch RH, Dieset I, Faerden A, Reponen EJ, Hope S, Hoseth EZ, et al. Inflammatory markers are altered in severe mental disorders independent of comorbid cardiometabolic disease risk factors. Psychol Med. 2019;49(10):1749\u201357. https:\/\/doi.org\/10.1017\/S0033291718004142.","journal-title":"Psychol Med"},{"issue":"1","key":"3522_CR29","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41386-018-0111-z","volume":"44","author":"AN Kaczkurkin","year":"2019","unstructured":"Kaczkurkin AN, Raznahan A, Satterthwaite TD. Sex differences in the developing brain: insights from multimodal neuroimaging. Neuropsychopharmacology. 2019;44(1):71\u201385. https:\/\/doi.org\/10.1038\/s41386-018-0111-z.","journal-title":"Neuropsychopharmacology"},{"issue":"10","key":"3522_CR30","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/nri.2016.90","volume":"16","author":"SL Klein","year":"2016","unstructured":"Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16(10):626\u201338. https:\/\/doi.org\/10.1038\/nri.2016.90.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3522_CR31","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s13063-015-1094-2","volume":"16","author":"JA Engh","year":"2015","unstructured":"Engh JA, Andersen E, Holmen TL, Martinsen EW, Mordal J, Morken G, et al. Effects of high-intensity aerobic exercise on psychotic symptoms and neurocognition in outpatients with schizophrenia: study protocol for a randomized controlled trial. Trials. 2015;16(1):557. https:\/\/doi.org\/10.1186\/s13063-015-1094-2.","journal-title":"Trials"},{"issue":"8","key":"3522_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/archpsyc.1992.01820080032005","volume":"49","author":"RL Spitzer","year":"1992","unstructured":"Spitzer RL, Williams JB, Gibbon M, First MB. The structured clinical interview for DSM-III-R (SCID). I: history, rationale, and description. Arch Gen Psychiatry. 1992;49(8):624\u20139. https:\/\/doi.org\/10.1001\/archpsyc.1992.01820080032005.","journal-title":"Arch Gen Psychiatry"},{"issue":"2","key":"3522_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261\u201376. https:\/\/doi.org\/10.1093\/schbul\/13.2.261.","journal-title":"Schizophr Bull"},{"issue":"S22","key":"3522_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1192\/S0007125000292581","volume":"22","author":"D Addington","year":"1993","unstructured":"Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry Suppl. 1993;22(S22):39\u201344. https:\/\/doi.org\/10.1192\/S0007125000292581.","journal-title":"Br J Psychiatry Suppl"},{"issue":"1\u20133","key":"3522_CR35","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.schres.2012.01.031","volume":"137","author":"RS Wallwork","year":"2012","unstructured":"Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr Res. 2012;137(1\u20133):246\u201350. https:\/\/doi.org\/10.1016\/j.schres.2012.01.031.","journal-title":"Schizophr Res"},{"issue":"2\u20133","key":"3522_CR36","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0920-9964(02)00490-5","volume":"68","author":"S Sarro","year":"2004","unstructured":"Sarro S, Duenas RM, Ramirez N, Arranz B, Martinez R, Sanchez JM, et al. Cross-cultural adaptation and validation of the Spanish version of the Calgary depression scale for schizophrenia. Schizophr Res. 2004;68(2\u20133):349\u201356. https:\/\/doi.org\/10.1016\/S0920-9964(02)00490-5.","journal-title":"Schizophr Res"},{"issue":"6","key":"3522_CR37","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.12740\/PP\/113222","volume":"53","author":"A Wichniak","year":"2019","unstructured":"Wichniak A, Dudek D, Heitzman J, Kaplon-Cieslicka A, Mamcarz A, Samochowiec J, et al. Metabolic risk reduction in patients with schizophrenia treated with antipsychotics: recommendations of the polish psychiatric association. Psychiatr Pol. 2019;53(6):1191\u2013218. https:\/\/doi.org\/10.12740\/PP\/113222.","journal-title":"Psychiatr Pol"},{"issue":"1\u20132","key":"3522_CR38","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.psychres.2010.01.007","volume":"177","author":"R Nesvag","year":"2010","unstructured":"Nesvag R, Lange EH, Faerden A, Barrett EA, Emilsson B, Ringen PA, et al. The use of screening instruments for detecting alcohol and other drug use disorders in first-episode psychosis. Psychiatry Res. 2010;177(1\u20132):228\u201334. https:\/\/doi.org\/10.1016\/j.psychres.2010.01.007.","journal-title":"Psychiatry Res"},{"issue":"7","key":"3522_CR39","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1373\/clinchem.2004.033175","volume":"50","author":"M Dobiasova","year":"2004","unstructured":"Dobiasova M. Atherogenic index of plasma [log(triglycerides\/HDL-cholesterol)]: theoretical and practical implications. Clin Chem. 2004;50(7):1113\u20135. https:\/\/doi.org\/10.1373\/clinchem.2004.033175.","journal-title":"Clin Chem"},{"issue":"2","key":"3522_CR40","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacl.2010.02.005","volume":"4","author":"A Onat","year":"2010","unstructured":"Onat A, Can G, Kaya H, Hergenc G. \"Atherogenic index of plasma\" (log10 triglyceride\/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol. 2010;4(2):89\u201398. https:\/\/doi.org\/10.1016\/j.jacl.2010.02.005.","journal-title":"J Clin Lipidol"},{"key":"3522_CR41","first-page":"240","volume":"29","author":"S Niroumand","year":"2015","unstructured":"Niroumand S, Khajedaluee M, Khadem-Rezaiyan M, Abrishami M, Juya M, Khodaee G, et al. Atherogenic index of plasma (AIP): a marker of cardiovascular disease. Med J Islam Repub Iran. 2015;29:240.","journal-title":"Med J Islam Repub Iran"},{"issue":"1","key":"3522_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamapediatrics.2019.3875","volume":"174","author":"LJH Rasmussen","year":"2019","unstructured":"Rasmussen LJH, Moffitt TE, Arseneault L, Danese A, Eugen-Olsen J, Fisher HL, et al. Association of Adverse Experiences and Exposure to violence in childhood and adolescence with inflammatory burden in young people. JAMA Pediatr. 2019;174(1):1\u201311. https:\/\/doi.org\/10.1001\/jamapediatrics.2019.3875.","journal-title":"JAMA Pediatr"},{"key":"3522_CR43","first-page":"90","volume-title":"Medical statistics : in clinical and epidemiological research","author":"DW Hosmer","year":"2012","unstructured":"Hosmer DW, Lemeshow S. Logistic regression. In: Veier\u00f8d MB, Lydersen S, Laake P, editors. Medical statistics : in clinical and epidemiological research. Oslo: Gyldendal akademisk; 2012. p. 90\u2013126."},{"key":"3522_CR44","doi-asserted-by":"publisher","first-page":"892","DOI":"10.3389\/fpsyt.2019.00892","volume":"10","author":"S Momtazmanesh","year":"2019","unstructured":"Momtazmanesh S, Zare-Shahabadi A, Rezaei N. Cytokine alterations in schizophrenia: An updated review. Front Psychiatry. 2019;10:892. https:\/\/doi.org\/10.3389\/fpsyt.2019.00892.","journal-title":"Front Psychiatry"},{"issue":"1\u20133","key":"3522_CR45","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.schres.2015.01.026","volume":"164","author":"C Noto","year":"2015","unstructured":"Noto C, Ota VK, Santoro ML, Ortiz BB, Rizzo LB, Higuchi CH, et al. Effects of depression on the cytokine profile in drug naive first-episode psychosis. Schizophr Res. 2015;164(1\u20133):53\u20138. https:\/\/doi.org\/10.1016\/j.schres.2015.01.026.","journal-title":"Schizophr Res"},{"issue":"1","key":"3522_CR46","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/eip.12946","volume":"15","author":"J Ventura","year":"2021","unstructured":"Ventura J, McEwen S, Subotnik KL, Hellemann GS, Ghadiali M, Rahimdel A, et al. Changes in inflammation are related to depression and amount of aerobic exercise in first episode schizophrenia. Early Interv Psychiatry. 2021;15(1):213\u20136. https:\/\/doi.org\/10.1111\/eip.12946.","journal-title":"Early Interv Psychiatry"},{"issue":"1\u20133","key":"3522_CR47","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.schres.2006.09.027","volume":"90","author":"RR Conley","year":"2007","unstructured":"Conley RR, Ascher-Svanum H, Zhu B, Faries DE, Kinon BJ. The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophr Res. 2007;90(1\u20133):186\u201397. https:\/\/doi.org\/10.1016\/j.schres.2006.09.027.","journal-title":"Schizophr Res"},{"key":"3522_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jad.2020.04.056","volume":"273","author":"W Li","year":"2020","unstructured":"Li W, Yang Y, An FR, Zhang L, Ungvari GS, Jackson T, et al. Prevalence of comorbid depression in schizophrenia: a meta-analysis of observational studies. J Affect Disord. 2020;273:524\u201331. https:\/\/doi.org\/10.1016\/j.jad.2020.04.056.","journal-title":"J Affect Disord"},{"issue":"2","key":"3522_CR49","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/schbul\/sbw097","volume":"43","author":"R Upthegrove","year":"2017","unstructured":"Upthegrove R, Marwaha S, Birchwood M. Depression and schizophrenia: cause, consequence, or trans-diagnostic issue? Schizophr Bull. 2017;43(2):240\u20134. https:\/\/doi.org\/10.1093\/schbul\/sbw097.","journal-title":"Schizophr Bull"},{"issue":"1","key":"3522_CR50","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1741-7015-9-90","volume":"9","author":"E Bromet","year":"2011","unstructured":"Bromet E, Andrade LH, Hwang I, Sampson NA, Alonso J, de Girolamo G, et al. Cross-national epidemiology of DSM-IV major depressive episode. BMC Med. 2011;9(1):90. https:\/\/doi.org\/10.1186\/1741-7015-9-90.","journal-title":"BMC Med"},{"issue":"1","key":"3522_CR51","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1038\/s41598-018-21243-x","volume":"8","author":"GY Lim","year":"2018","unstructured":"Lim GY, Tam WW, Lu Y, Ho CS, Zhang MW, Ho RC. Prevalence of depression in the community from 30 countries between 1994 and 2014. Sci Rep. 2018;8(1):2861. https:\/\/doi.org\/10.1038\/s41598-018-21243-x.","journal-title":"Sci Rep"},{"issue":"5","key":"3522_CR52","doi-asserted-by":"publisher","first-page":"e0156624","DOI":"10.1371\/journal.pone.0156624","volume":"11","author":"JM Ramsey","year":"2016","unstructured":"Ramsey JM, Cooper JD, Bot M, Guest PC, Lamers F, Weickert CS, et al. Sex differences in serum markers of major depressive disorder in the Netherlands study of depression and anxiety (NESDA). PLoS One. 2016;11(5):e0156624. https:\/\/doi.org\/10.1371\/journal.pone.0156624.","journal-title":"PLoS One"},{"issue":"1","key":"3522_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S2215-0366(17)30293-6","volume":"5","author":"TA Pollak","year":"2018","unstructured":"Pollak TA, Drndarski S, Stone JM, David AS, McGuire P, Abbott NJ. The blood-brain barrier in psychosis. Lancet Psychiatry. 2018;5(1):79\u201392. https:\/\/doi.org\/10.1016\/S2215-0366(17)30293-6.","journal-title":"Lancet Psychiatry"},{"issue":"9","key":"3522_CR54","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.numecd.2019.05.066","volume":"29","author":"M Cabral","year":"2019","unstructured":"Cabral M, Bangdiwala SI, Severo M, Guimaraes JT, Nogueira L, Ramos E. Central and peripheral body fat distribution: different associations with low-grade inflammation in young adults? Nutr Metab Cardiovasc Dis. 2019;29(9):931\u20138. https:\/\/doi.org\/10.1016\/j.numecd.2019.05.066.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"3522_CR55","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.schres.2018.10.020","volume":"206","author":"M Brink","year":"2019","unstructured":"Brink M, Green A, Bojesen AB, Lamberti JS, Conwell Y, Andersen K. Excess medical comorbidity and mortality across the lifespan in schizophrenia.: a nationwide Danish register study. Schizophr Res. 2019;206:347\u201354. https:\/\/doi.org\/10.1016\/j.schres.2018.10.020.","journal-title":"Schizophr Res"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-021-03522-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-021-03522-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,26]],"date-time":"2021-10-26T11:08:29Z","timestamp":1635246509000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-021-03522-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":55,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3522"],"URL":"https:\/\/doi.org\/10.1186\/s12888-021-03522-6","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]},"assertion":[{"value":"11 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Regional Committees for Medical Research Ethics \u2013 South East Norway (2014\/372\/REK S\u00d8R-\u00d8ST), the Norwegian Data Inspectorate and the Norwegian Directorate of Health. All participants gave written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare no conflict of interest related to this study. OAA discloses he is a consultant to HealthLytix, and received speaker\u2019s honoraria from Lundbeck and Sunovion.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"527"}}